Back to top

Analyst Blog

Cempra, Inc. (CEMP - Snapshot Report) recently announced that its antibiotic candidate, solithromycin, showed safety and tolerability in patients ailing from mild to severe chronic liver diseases. The pharmacokinetic analyses revealed that no adjustments in dosage were needed for compensating the decreased liver function in the concerned patient population.

This hepatic impairment study was carried out on 24 patients suffering from chronic liver disease. The patient population was divided into three sub-categories - 8 with mild disease, 8 with moderate disease and 8 with severe disease.

The study was based on a 5-day dosage of solithromycin which included 800 mg on the first day and 400 mg once each day for the remaining 4 days. The pharmacokinetics of solithromycin was examined on the selected patient population and compared to the same dosage regimen given to a matched healthy cohort.

Cempra has an exclusive license and development agreement for solithromycin with Japanese company, Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corp. (FUJIY - Analyst Report).

We note that solithromycin is being developed for the treatment of community-acquired bacterial pneumonia (CABP) and gonorrhea. Currently, a phase III trial is evaluating the use of oral solithromycin in moderate-to-moderately severe CABP.

The company is also planning to initiate an intravenous-to-oral solithromycin phase III trial in CABP patients in the fourth quarter of 2013.

Cempra carries a Zacks Rank #2 (Buy). Currently, companies which look well-positioned include Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals (JAZZ - Analyst Report) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%